|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
8
|
|
pubmed:dateCreated |
2007-7-27
|
|
pubmed:abstractText |
Vascular endothelial growth factor (VEGF) is a proangiogenic molecule produced by melanoma cells. We hypothesized that administration of bevacizumab (Bev), a monoclonal antibody that neutralizes VEGF, with low-dose interferon alfa-2b (IFN-alpha2b), an inhibitor of basic fibroblast growth factor (FGF), would lead to the regression of metastatic melanoma.
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Angiogenesis Inhibitors,
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal,
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal, Humanized,
http://linkedlifedata.com/resource/pubmed/chemical/Immunologic Factors,
http://linkedlifedata.com/resource/pubmed/chemical/Interferon-alpha,
http://linkedlifedata.com/resource/pubmed/chemical/Recombinant Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/bevacizumab,
http://linkedlifedata.com/resource/pubmed/chemical/interferon alfa-2b
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Aug
|
|
pubmed:issn |
1068-9265
|
|
pubmed:author |
pubmed-author:BiberJennifer EJE,
pubmed-author:CarsonWilliam EWE3rd,
pubmed-author:ChenHelen XHX,
pubmed-author:JensenRhondaR,
pubmed-author:KefauverCherylC,
pubmed-author:KendraKariK,
pubmed-author:LehmanAmyA,
pubmed-author:LesinskiGregory BGB,
pubmed-author:VarkerKimberly AKA,
pubmed-author:WalkerMichael JMJ,
pubmed-author:WuHaifengH,
pubmed-author:YoungDonnD
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
14
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
2367-76
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:17534686-Adult,
pubmed-meshheading:17534686-Aged,
pubmed-meshheading:17534686-Aged, 80 and over,
pubmed-meshheading:17534686-Angiogenesis Inhibitors,
pubmed-meshheading:17534686-Antibodies, Monoclonal,
pubmed-meshheading:17534686-Antibodies, Monoclonal, Humanized,
pubmed-meshheading:17534686-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:17534686-Chemotherapy, Adjuvant,
pubmed-meshheading:17534686-Dose-Response Relationship, Drug,
pubmed-meshheading:17534686-Drug Administration Schedule,
pubmed-meshheading:17534686-Female,
pubmed-meshheading:17534686-Humans,
pubmed-meshheading:17534686-Immunologic Factors,
pubmed-meshheading:17534686-Interferon-alpha,
pubmed-meshheading:17534686-Male,
pubmed-meshheading:17534686-Melanoma,
pubmed-meshheading:17534686-Middle Aged,
pubmed-meshheading:17534686-Neoplasm Metastasis,
pubmed-meshheading:17534686-Recombinant Proteins,
pubmed-meshheading:17534686-Skin Neoplasms
|
|
pubmed:year |
2007
|
|
pubmed:articleTitle |
A randomized phase 2 trial of bevacizumab with or without daily low-dose interferon alfa-2b in metastatic malignant melanoma.
|
|
pubmed:affiliation |
Division of Surgical Oncology, The Ohio State University Comprehensive Cancer Center, N924 Doan Hall, 410 W 10th Avenue, Columbus, Ohio 43210, USA.
|
|
pubmed:publicationType |
Journal Article,
Comparative Study,
Randomized Controlled Trial,
Clinical Trial, Phase II,
Research Support, N.I.H., Extramural
|
